The following video is from Tuesday's MarketFoolery podcast, in which host Chris Hill, along with analysts Jason Moser and Matt Argersinger, discuss the top business and investing stories of the day.
Johnson & Johnson (NYSE: JNJ ) reported higher than-than-expected earnings. Shares of the consumer giant are up 28% in the past year. Will Johnson & Johnson continue to produce for investors? Should Johnson & Johnson follow Procter & Gamble's (NYSE: PG ) lead and double down on some of its more profitable assets. In this installment of MarketFoolery, our analysts talk about the future of Johnson & Johnson.
Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson has its critics convinced that the company is spread way too thin. If you want to know whether J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out the Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.
The relevant video segment can be found between 10:34 and 17:01.